P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This prospective study was conducted to evaluate the efficacy and safety profiles of
first-line combined gemcitabine, oxaliplatin, and Pegaspargase (P-Gemox) in newly diagnosed,
nasal type, extranodal natural killer/T-cell lymphoma.